Analyst consensus rating
Akebia Therapeutics Analyst Rating: Strong Buy
Direct answer
Akebia Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.92.
Forecast evidence checked October 27, 2026.
Get free Akebia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.66
- Average price target
- $3.92
- High price target
- $6.00
- Low price target
- $1.00
- Low target gap
- +51.4%
- Target upside
- +493.1%
- High target gap
- +808.5%
- Target range width
- 757.1%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Akebia Therapeutics?
Akebia Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $3.92.
How far are Akebia Therapeutics's low and high targets from the recorded price?
The low target implies +51.4%, while the high target implies +808.5%.
How many analysts are included in Akebia Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Akebia Therapeutics's target upside or downside calculated?
The average target of $3.92 is divided by the recorded price of $0.66, then one is subtracted to produce +493.1%. This does not guarantee a future return.
When was Akebia Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.